Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus DCF neoadjuvant therapy for resectable esophageal squamous cell carcinoma
ChiCTR2300075075Phase 2Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Aug 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, docetaxel, cisplatin and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Provincial Hospital. Primary endpoint: Pathologic complete response rate. Started Aug 2023; status: recruiting.
02
Drugs
toripalimabdocetaxelcisplatinfluorouracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300075075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075075.